A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain

Related Experiment Videos

J D Johnson1, J C Edman, W J Rutter

  • 1Hormone Research Institute, University of California, San Francisco 94143-0534.

Insights

Researchers discovered discoidin domain receptor (DDR), a novel breast carcinoma tyrosine phosphoprotein. This protein kinase may interact with cell surface molecules, defining a new class of receptor tyrosine kinases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Receptor tyrosine kinases (RTKs) are crucial cell signaling proteins.
  • Dysregulation of RTKs is implicated in various cancers, including breast carcinoma.
  • Novel RTKs may offer new therapeutic targets.

Purpose of the Study:

  • To identify and characterize novel receptor tyrosine kinases involved in breast carcinoma.
  • To elucidate the structural features and potential function of the newly identified protein.

Main Methods:

  • cDNA identification and sequencing.
  • Bioinformatic analysis of predicted protein domains.
  • Comparative analysis with known protein families.

Main Results:

  • Identification of discoidin domain receptor (DDR) as a breast carcinoma tyrosine phosphoprotein.
  • DDR possesses a unique structure with a C-terminal tyrosine kinase domain and an N-terminal discoidin I-like domain.
  • An extended proline/glycine-rich region and a transmembrane sequence were predicted.

Conclusions:

  • DDR represents an unusual class of receptor tyrosine kinases.
  • The unique structural features suggest novel ligand or substrate interaction mechanisms.
  • Discoidin I domains may mediate interactions with cell surface molecules, potentially impacting cancer progression.

Related Concept Videos